

♦ RWMH23s01 (iPS cells expressing the second highest HLA in Japan*1)

Clone ID	RWMH23s01	Product	Human iPS cells
Source	Peripheral Blood, Human	Race	Japanese
Passage No.	9	Gender	Male
Lot No.	20161016-06	Manufacture Dates	Oct. 16 th , 2016
Culture medium	StemFit AK03N	Substrate	iMatrix-511MG
Culture Method	Feeder-free (**2)		
Plasmids for	pCE-hSK, pCE-hUL, pCE-hOCT3/4, pCE-mp53DD, pCXB-EBNA1		
reprograming			
Use and Provision	Please check our web site ;		
of this cell stock	https://www.cira-foundation.or.jp/e/project/stock.html		

^(※1) **Reference**; Okita, et. al., Nat Methods. 2011 8(5): 409-412

Test Result

Test	Method	Result
Sterility	BacT/ALERT	Negative
Mycoplasma	PCR	Negative
Endotoxin	LAL	≦ 5 EU/mL
Virus (HBV, HCV, HIV, HTLV, Parvovirus B19)	PCR	Negative
HLA typing (HLA-A, B, DR)	PCR-SBT	Consistent with the donor cells
STR genotyping	PCR	Consistent with the donor cells
Morphology	Microscope	Consistent with human ES cells
Karyotype	Conventional Giemsa analysis G-banding	46,XY[20]
Plasmid remnants	qPCR	Below the limit of quantification
CNV(*3)	WGS, SNP	No de novo CNVs (>1kbp) were found in COSMIC Cancer Gene Census (ver.79) and Shibata list $(**5)$.
SNV/Indel ^(※4)	WGS, WES	No de novo non-synonymous SNVs/Indels were found in COSMIC Cancer Gene Census (ver.79) and Shibata list ^(**5) .
Undifferentiated	Microarray ^(※7)	POU5F1: 4.7%、NANOG: 5.1% (Relative expression levels of GAPDH)
markers	Flow cytometry (**7)	TRA-1-60: 97.5% SSEA4: 100.0% TRA-2-49: 100.0%


^(%2) **Reference**; Nakagawa, et. al., Nat Biotechnol. 2008 26(1):101-106



Thawed postnatal cells	Counting the number of the cells (**6, 7)	1.93×10 ⁵ cells (Survival rate; 92.5%)
Number of proliferating cells after thawing	Counting the number of the cells after culturing for 7 days(**6,7).	16.8×10^5 cells (Number of seeded cells; 6.4 $\times 10^4$ cells)
Doubling time (h)	Counting the number of the cells (*6,7)	P12→P13: 30.5 P13→P14: 25.0 P14→P15: 27.2 P15→P16: 23.5 P16→P17: 23.6

- (%3) CNV; Copy Number Variation
- (¾4) SNV/Indel; Single nucleotide variants /Insertion Deletion
- (%5) The PMDA Science Board "Current Perspective on Evaluation of Tumorigenicity of Cellular- and Tissue-based Products Derived from induced Pluripotent Stem Cells (iPSCs) and iPSCs as Their Starting Materials" (Cellular- and Tissue-based Products Subcommittee, 20 August 2013)
- (※6) ThermoFisher Countess®
- (※7) The result of # 1 out of 3 frozen stocks is shown.

■Image



Please contact us if you have any questions.

(ips-request@cira-foundation.or.jp)

